Terpos, E., Kastritis, E., Delimpasi, S., Papathanasiou, M., Lampropoulou, V., Kanellias, N., Ntanasis-Stathopoulos, I., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Eleutherakis-Papaiakovou, E., Vyas, Y., Kotsopoulou, M., Katodrytou, E., Gavriatopoulou, M., Dimopoulos, M. (2025). Isatuximab with bortezomib, cyclophosphamide, and dexamethasone followed by isatuximab and lenalidomide maintenance in newly diagnosed multiple myeloma patients with severe renal impairment: Final analysis of a phase 2 study by the greek myeloma study group. Blood. https://doi.org/10.1182/blood-2025-4036